Gene-Guided blood thinners aim to cut bleeding risks

NCT ID NCT07602257

Not yet recruiting Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using a patient's genetic information to choose anti-platelet drugs can lower bleeding risks compared to standard care. About 1,760 high-risk patients receiving a heart stent will be assigned to either a personalized drug plan or usual therapy. The goal is to see if tailoring treatment reduces serious bleeding events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ticagrelor, Aspirin, Clopidogrel (Plavix)
What this could lead to: If successful, this could lead to a safer, personalized way to prescribe anti-platelet drugs, reducing bleeding complications in heart patients.
What could go wrong: This is a pilot study, so results are preliminary. The approach may not reduce bleeding as hoped, and genetic testing adds complexity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH RISK BLEEDING

Contacts and locations

Locations

University of Ottawa Heart Institute

Ottawa, Ontario, K1Y 4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.